response rate on phase 1/2 trial regn5458 (bcmaxcd3 bispecific antibody) for rrmm patients
Published 2 years ago • 298 plays • Length 7:18Download video MP4
Download video MP3
Similar videos
-
7:26
regn5458, a bcmaxcd3 bispecific monoclonal antibody, in a phase 1/2 1st-in-human study in rrmm pts
-
4:45
a first-in-human trial of regn5458 in r/r myeloma: updated phase i data
-
59:53
clinical trials in multiple myeloma
-
5:32
myeloma made simple: bispecific antibody targets made simple | myeloma targeting with bispecifics
-
2:47
what are bispecific antibodies?
-
5:44
bispecific antibodies: early side effects
-
6:41
phase 1 cart-ddbcma utilizing a novel synthetic binding domain for the treatment of pts with rrmm
-
8:06
how do response rates observed in clinical trials translate into real-world outcomes in mm?
-
2:15:41
imf virtual regional community workshop (rcw) - new england
-
2:27
addressing the disparity in ethnic variation in uk-based clinical trials for multiple myeloma
-
6:39
dreamm-9: belantamab mafodotin standard care in newly diagnosed multiple myeloma
-
6:45
phase i trial of a fcrh5-targeted bite in r/r myeloma
-
1:57
clinical trial development in multiple myeloma: considerations for hematologists
-
4:11
bispecific antibodies in myeloma: approvals and clinical trials
-
2:23
imaging in diagnosis and response assessment in myeloma
-
5:06
bispecific antibodies: late side effects
-
2:47
how could clinical trials fit into your myeloma treatment plan?
-
2:06:48
imf virtual regional community workshop (rcw) - pacific northwest
-
4:38
update on the phase 3 optimismm trial